In FY25, Viemed grew net revenue 21% y/y to $270.3M, generated $14.9M of net income, and delivered record adj. EBITDA of $61.4M. Growth benefited from continued platform momentum and contributions from Lehan’s, with additional tailwinds from the broader shift to in-home care and accelerating sleep/resupply adoption. The key headwind was short-term friction from the updated NCD, which added documentation requirements and tightened coverage criteria, temporarily moderating ventilator patient growth. We note that this did not change reimbursement levels, and vent activity has already started to normalize. Viemed ended the year with free cash flow up 141% y/y